Event JSON
{
"id": "af4fb9e4301ff24499c266bdb694ec6a3cd6881addc4ceab722e4662af0f066b",
"pubkey": "de1abdd3127788ab39fb6f558233067d7cf07e8165598738c9a46a9cff3979a0",
"created_at": 1747547673,
"kind": 1,
"tags": [
[
"r",
"https://finance.yahoo.com/news/why-iovance-biotherapeutics-tumbled-nearly-223909778.html"
],
[
"subject",
"Why Iovance Biotherapeutics Tumbled by Nearly 6% Today"
],
[
"published_at",
"1747435149"
],
[
"image",
"https://s.yimg.com/ny/api/res/1.2/W2IgyITSOXNnFeA265JwxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0a886363d77cee337ab330e5d82d25cb"
],
[
"p",
"de1abdd3127788ab39fb6f558233067d7cf07e8165598738c9a46a9cff3979a0",
"wss://articles.layer3.news"
],
[
"p",
"6742ae4103f4faeb83264d955f742f9a611ac80190cc0043e3b322318cc7ee61",
"wss://articles.layer3.news"
],
[
"imeta",
"url https://s.yimg.com/ny/api/res/1.2/W2IgyITSOXNnFeA265JwxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0a886363d77cee337ab330e5d82d25cb"
],
[
"t",
"David Dai"
],
[
"t",
"Eric Volkman"
],
[
"t",
"business"
],
[
"t",
"mainstream:perspective"
],
[
"summary",
"The analyst, David Dai of UBS, lowered his price target to $2 per share from $17, citing below-expectation sales of the company's advanced melanoma drug Amtagvi and higher drop-out rates for the drug. Dai expressed concern about the slow ramp-up of the company's commercialization and flaws in patient selection. The company's revenue guidance cut in the earnings report also raised concerns."
]
],
"content": "nostr:nprofile1qyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqvap2usgr7nawhqexfk247ap0nfs34jqpjrxqqslrkv3rrrx8aesst3mr8r\nWHY IOVANCE BIOTHERAPEUTICS TUMBLED BY NEARLY 6% TODAY\n\nhttps://s.yimg.com/ny/api/res/1.2/W2IgyITSOXNnFeA265JwxQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04MDA-/https://media.zenfs.com/en/motleyfool.com/0a886363d77cee337ab330e5d82d25cb\n--\n✍️ Iovance Biotherapeutics' shares fell 6% after an analyst downgraded his recommendation to neutral from buy, citing concerns over the company's latest quarterly earnings report.\n--\n👉 Analyst David Dai downgraded Iovance Biotherapeutics' recommendation to neutral from buy\n👉 Price target lowered to $2 per share from $17\n👉 Below-expectation sales of advanced melanoma drug Amtagvi\n👉 Higher drop-out rates for the drug\n👉 Slow ramp-up of commercialization\n👉 Flaws in patient selection\n👉 Revenue guidance cut in earnings report\n\n--\n#DavidDai #EricVolkman #business\n--\nnostr:nevent1qvzqqqqqqypzqe6z4eqs8a86awpjvnv4ta6zlxnprtyqryxvqpp78vezxxxv0mnpqyd8wumn8ghj7ctjw35kxmr9wvhxcctev4erxtnwv4mhxqpqpdx5rtza9sfjxrnkhss3v6852tlxx58jwvtegznef2j5kycurvjsfa267h \n ",
"sig": "f46d6483449e4a299a14ff9594d0e6ea4d9938134c4bd7aec830d5576629dc210982b340082cccfbfd4f84c6cff5eeb495ec4cef5ba5d78cf71e0390bbdf3fd5"
}
